Streetbeat News

Stock Prices

JNJ

An option alert has been issued for Johnson & Johnson (JNJ) for Friday $160 calls sweep. The alert involves 5000 contracts at $0.132 each, compared to the open interest of 1335 contracts. The reference price is $155.84.

Portfolio Pulse from Charles Gross

September 27, 2023 | 5:34 pm

PEP

A significant bearish stance has been taken on PepsiCo (NASDAQ:PEP) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is 30% bullish and 70% bearish. The targeted price range for PepsiCo over the last 3 months has been $165.0 to $190.0. The current price of PEP is down -1.16% at $170.52.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:31 pm

GOLD

A significant bullish stance has been taken on Barrick Gold (NYSE:GOLD) as evidenced by unusual options activity. The options scanner at Benzinga spotted 11 uncommon options trades for Barrick Gold, with 63% bullish and 36% bearish sentiment. The whales have been targeting a price range from $10.0 to $20.0 for Barrick Gold over the last 3 months. BMO Capital maintains their Outperform rating on Barrick Gold with a price target of $30.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:31 pm

AKA

COOK

CURV

EBET

FFIE

GAN

GDHG

GEHI

SSU

TAL

VFS

During Wednesday's intraday session, several consumer discretionary stocks experienced significant movements. Gravitas Education Hldgs, a.k.a. Brands Holding, GAN, Torrid Holdings, TAL Education, and Golden Heaven Group Hldgs saw their stocks rise, while Faraday Future, PARTS iD, Traeger, EBET, VinFast Auto, and SIGNA Sports United experienced declines.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:31 pm

BHVN

LIFW

STSS

UTRS

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Gainers included MSP Recovery (LIFW), Biohaven (BHVN), SeaStar Medical Holding (ICU), Context Therapeutics (CNTX), Streamline Health Solns (STRM), and Galecto (GLTO). Losers included Sharps Technology (STSS), Minerva Surgical (UTRS), Know Labs (KNW), Tharimmune (THAR), Femasys (FEMY), and Synlogic (SYBX).

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:31 pm

AUVIP

MLKN

PIXY

VLD

During Wednesday's intraday session, several industrials stocks experienced significant movement. Gainers included ShiftPixy (PIXY), MillerKnoll (MLKN), Freight Technologies (FRGT), Greenwave Tech Solns (GWAV), Wheels Up Experience (UP), and Agrify (AGFY). Losers included Applied UV (AUVIP), Velo3D (VLD), Pixie Dust Technologies (PXDT), Byrna Technologies (BYRN), Globus Maritime (GLBS), and SOS (SOS).

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:31 pm

BBAI

TRT

During Wednesday's intraday session, several information technology stocks experienced significant movements. BigBear.ai Hldgs (BBAI), Addvantage Technologies (AEY), Pros Holdings (PRO), SoundHound AI (SOUN), Telos (TLS), and NETSOL Technologies (NTWK) saw their stocks rise, with BBAI leading the gainers with a 13.3% increase. On the other hand, Trio-Tech Intl (TRT), GSE Systems (GVP), Peraso (PRSO), MicroAlgo (MLGO), Verb Tech (VERB), and Sigma Additive Solutions (SASI) experienced a decrease in their stock prices, with TRT leading the losers with a 31.6% drop.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:31 pm

NOC

Northrop Grumman (NYSE:NOC) has outperformed the market over the past 20 years by 4.96% on an annualized basis, producing an average annual return of 12.25%. If an investor had bought $100 of NOC stock 20 years ago, it would be worth $1,001.39 today.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:30 pm

CDNS

Cadence Design Sys (NASDAQ:CDNS) has outperformed the market over the past 15 years, producing an average annual return of 27.03%. If an investor had bought $1000 of CDNS stock 15 years ago, it would be worth $34,260.09 today.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 5:30 pm

PFE

Pfizer, Inc. (NYSE:PFE) shares hit a new 52-week low, falling more than 24% over the last year. The company faces challenges including issues with the commercial roll-out of updated COVID-19 vaccines and uncertainty regarding the approval of its oral antiviral COVID-19 treatment, Paxlovid, for commercial sale in the U.S. market.

Portfolio Pulse from Erica Kollmann

September 27, 2023 | 5:22 pm